All Updates

All Updates

icon
Filter
Product updates
MindBio provides update on microdosing formulation MB22001
Psychedelic Medicine
Oct 8, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Oct 8, 2024

MindBio provides update on microdosing formulation MB22001

Product updates

  • MindBio Therapeutics, a biopharmaceutical company developing microdoses of psychedelic medicines for psychiatric treatments, has announced that its microdosing formulation MB22001 has achieved 12-month shelf stability at room temperature.

  • MB22001 is a proprietary, self-titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home use by patients with depression. As of October 2024, MB22001 is being tested in multiple Phase IIB clinical trials.

  • The 12-month shelf stability ensures that the product remains safe and effective for patients during this period, meeting key regulatory requirements for product quality and patient safety.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.